Supernus Pharmaceuticals, Inc.
Veridion Score
Composite trend over time
Why is SUPN moving today?
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for SUPN.
SUPN insider activity
Supernus Pharmaceuticals, Inc.
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for SUPN.
SUPN contract awards, year to date.
Public federal awards linked to this ticker.
SUPN lobbying filings, year to date.
Registered lobbying filings matched to Supernus Pharmaceuticals, Inc..